Kolon TissueGene

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • Foreign currency monetary assets/liabilities negligible at fiscal year-end, foreign exchange impact on profit/loss insignificant
• • Variable interest rate borrowings zero at fiscal year-end, no exposure to interest rate fluctuation risk

Management Discussion & Analysis

• • Revenue USD 3,627K (-2.5% YoY); Operating loss USD 15,696K (-2.7% improvement); Net loss USD 135,413K (-446.5%)
• • Bio segment operating loss improved 7.1% to USD (13,898)K due to reduced legal and SG&A expenses

Business Overview

• • Core revenue: 100% from Complex Distribution business (Health Beauty and Liquor Beverage), Bio segment (TG-C gene therapy) reported no sales in FY2025
• • FDA Clinical Hold on TG-C Knee OA Phase 3 lifted in April 2020; Phase 3 patient enrollment completed with 1,066 patients as of July 2024, follow-up ongoing

What are the latest Kolon TissueGene DART filings in 2026?

Kolon TissueGene (KRX code 950160) has filed an annual report on March 18, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did Kolon TissueGene file its most recent annual report?

Kolon TissueGene filed its most recent annual report on March 18, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is Kolon TissueGene's KRX stock code?

Kolon TissueGene's KRX stock code is 950160. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 950160 to look up all Kolon TissueGene disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does Kolon TissueGene file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for Kolon TissueGene.

Where can I find Kolon TissueGene financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from Kolon TissueGene annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.